<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639261</url>
  </required_header>
  <id_info>
    <org_study_id>IFN_BOSZT_01</org_study_id>
    <secondary_id>2010-022467-36</secondary_id>
    <nct_id>NCT01639261</nct_id>
  </id_info>
  <brief_title>A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT</brief_title>
  <acronym>IFN_BOSZT_01</acronym>
  <official_title>Eine Phase II Studie über Interferon Gamma 1b Zur Behandlung Der steroidrefraktären Bronchiolitis Obliterans Nach Allogener SZT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvement of quality of life in patients with BO and establishment of a new third line
      therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:

      Objective improvement of lung function, i.e.:

        -  Improvement of SO2, pO2 or pCO2 in oxygen dependent or improvement of FiO2 in
           respiration dependent patients ≥ 20 % or

        -  Reduction of oxygen need in oxygen dependent patients ≥ 1L O2/min with constant
           parameters at blood gas analysis (BGA) or

        -  Improvement of obstructive parameters ≥ 20 % or

        -  Improvement of lung function score (LFS) at least about one grade Improvement of lung
           function should be detectable at least by two consecutive examinations of lung function
           or BGA within at least four weeks.

      Secondary Objectives

        -  Morphological improvement of BO/BOOP at CT scan

        -  Reduction of steroids about at least 20 %
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>therapy response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Enhancement of therapy response from 15 % to 50 %</description>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Steroid-refractory Bronchiolitis Obliterans</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon gamma 1b</intervention_name>
    <description>Initial dose: 50µg s.c. three times/week, without fever &gt;38,5 dose increase: 50µg/m² BSA three times/week</description>
    <other_name>Imukin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Allogeneic SCT

          -  Age ≥ 18 years

          -  BO, firmed by 2 out of 3 examinations:

               -  Lung function/ BGA

               -  CT scan in in- and expiration or

               -  Histological diagnosis

          -  Therapy refractory BO, i.e. no improvement during at least three therapies, among:

               -  Azithromycin + inhaled steroids/ bronchodilators

               -  Systemic steroids 1 mg/kg BW

               -  One of the following therapies: MMF, mTOR inhibitors or ECP

          -  Effective contraception (before, during and for 8 weeks after the treatment)

          -  Blood count: no severe neutropenia, defined as ANC &gt; 1000/ml, platelets &gt; 50/nl and
             haemoglobin &gt; 8 g/dl

          -  Liver parameters (bilirubin, gammaGT, AP, ASAT, ALAT) lower than 3 x paramount normal
             range

          -  Kreatinin lower than 3 x paramount normal range

          -  Informed consent

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Pregnant or nursing woman

          -  No appropriate contraception

          -  Participation in any other study within 4 weeks before or during the study

          -  Active acute GvHD of other organs than the lung &gt; grade II or severe active chronic
             GvHD

          -  No appropriate antibiotic/ antimycotic therapy in documented infection

          -  Severe bone marrow suppression (ANC &lt; 1000/ml) or graft failure

          -  Liver parameters (bilirubin, gammaGT, AP, ASAT and ALAT) higher than 3 x paramount
             normal range

          -  Kreatinin higher than 3 x paramount normal range

          -  Participation in another study within 4 weeks before or during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernst Holler, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Regensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>July 11, 2012</last_update_submitted>
  <last_update_submitted_qc>July 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Regensburg</investigator_affiliation>
    <investigator_full_name>Professor Ernst Holler MD</investigator_full_name>
    <investigator_title>Senior physician</investigator_title>
  </responsible_party>
  <keyword>steroid-refractory</keyword>
  <keyword>bronchiolitis obliterans</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>interferon gamma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

